Singh T T, Singh I Y, Sharma D T, Singh N R
Department of Radiotherapy, Regional Institute of Medical Sciences, Imphal - 795 004, Manipur State, India.
Indian J Cancer. 2003 Jul-Sep;40(3):101-7.
A prospective randomized study was conducted in our department of Radiotherapy, Regional Institute of Medical Sciences, Imphal to evaluating the role of chemoradiation in the management of advanced inoperable cervical cancer (stage IIB-IIIB) taking only radiation treatment as control spanning the period 1996-1999. Of the fifty patients accumulated in the study group, three patients did not complete treatment, one expired due to other causes and three were lost to follow up. Likewise, of the forty-six patients in the control group, one patient did not complete treatment and 4 were lost to follow up. Thus only 43 and 41 patients were available for the result analysis for the study and control groups respectively. The early treatment response as assessed after two months of treatment conclusion were 79.1%, 13.9%, 93.0% and 58.5%, 31.7%, 90.2% as complete response (CR), partial response (PR), and total response (TR) respectively for the study and control groups. Our patients included in this study had a median follow up of 35 months and 33 months for study and control groups respectively. For this follow up, the disease-free survival, survival with disease and overall survival were 67.4%, 7.0%, 74.4% and 43.9%, 12.2%, 56.1% for study and control groups respectively. There was an increase in early side-effects in the chemoradiation group but the difference was not significant. Because of the early side effects, treatment delays ensued in 7 patients (16.3%) and in 3 patients (7.3%) in the study and control groups respectively. There was no significant increase in the late treatment toxicities in both the groups.
我们在英帕尔地区医学科学研究所放疗科进行了一项前瞻性随机研究，以评估放化疗在晚期无法手术的宫颈癌（IIB-IIIB期）治疗中的作用，仅将放疗作为对照，研究时间跨度为1996年至1999年。在研究组积累的50例患者中，3例未完成治疗，1例因其他原因死亡，3例失访。同样，在对照组的46例患者中，1例未完成治疗，4例失访。因此，研究组和对照组分别仅有43例和41例患者可用于结果分析。治疗结束两个月后评估的早期治疗反应，研究组和对照组的完全缓解（CR）、部分缓解（PR）和总缓解（TR）分别为79.1%、13.9%、93.0%和58.5%、31.7%、90.2%。本研究纳入的患者研究组和对照组的中位随访时间分别为35个月和33个月。对于此次随访，研究组和对照组的无病生存率、带病生存率和总生存率分别为67.4%、7.0%、74.4%和43.9%、12.2%、56.1%。放化疗组的早期副作用有所增加，但差异不显著。由于早期副作用，研究组和对照组分别有7例（16.3%）和3例（7.3%）患者出现治疗延迟。两组的晚期治疗毒性均无显著增加。
